Femasys Inc. announced that it has activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, New York. The FemBloc INtratubal Occlusion for TranscervicAL PEr permanent birth control (the "FINALE" trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The FDA approved multi- center pivotal trial is designed to address the high unmet need that exists for women seeking permanent birth control for whom elective surgery remains the only option.

Femasys is creating accessible innovative options for women, as exemplified by its lead product candidate, FemBloc(R) in late-stage clinical development for permanent birth control and its now-United States Food and Drug Administration (FDA)-cleared product, FemaSeed(R) for infertility treatment. The Company is commercializing complementary diagnostic products that were internally developed through its in-house manufacturing capabilities, with regulatory approvals in the U.S., Canada and other ex-U.S. territories. For over 100 years, there has been stagnant innovation in the area of permanent birth control; this could lead to a $20 billion market expansion opportunity for FemBloc in the U.S. alone.